Instituto Rosenbusch (BUE:ROSE) Total Stockholders Equity: ARS7,670 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
22 GF Score
Price ARS149.50
GF Value ARS65.90
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Total Stockholders Equity?

Instituto Rosenbusch BUE:ROSE -0.33% 22 Total Stockholders Equity is ARS7,670 Mil as of Jun. 2026. GuruFocus rates BUE:ROSE with a GF Score™ of 22/100 and a GF Value™ of ARS65.90 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Instituto Rosenbusch's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ARS7,670 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Instituto Rosenbusch's Book Value per Share for the quarter that ended in Jun. 2026 was ARS180.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Instituto Rosenbusch's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.40.

Instituto Rosenbusch  (BUE:ROSE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Instituto Rosenbusch's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(7669.694429-0)/42.589465
=180.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Instituto Rosenbusch's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(414.300856 + 2653.575618) / 7669.694429
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Total Stockholders Equity Related Terms

Instituto Rosenbusch Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Total Stockholders Equity Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 177.02 362.80 1,914.48 2,842.42 -800.17

Instituto Rosenbusch Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,498.94 372.53 -800.17 -2,818.61 7,669.69
BUE:ROSE
22GF Score
Instituto Rosenbusch SA BUE:ROSE
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of ARS7,670 Mil mean?
Instituto Rosenbusch (BUE:ROSE) has a Total Stockholders Equity of ARS7,670 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Total Stockholders Equity too high?
Instituto Rosenbusch's current Total Stockholders Equity is ARS7,670 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Total Stockholders Equity compare to ZTS and UTHR?
Instituto Rosenbusch's Total Stockholders Equity of ARS7,670 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Total Stockholders Equity is ARS7,670 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS65.90, compared to a current price of ARS149.50 — trading 126.9% above its estimated fair value. The current Total Stockholders Equity is ARS7,670 Mil. Instituto Rosenbusch's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Total Stockholders Equity is ARS7,670 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS149.50 is trading 126.9% above its estimated GF Value™ of ARS65.90. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Total Stockholders Equity: ARS7,670 Mil
  • GF Value™: ARS65.90 vs. price of ARS149.50 (126.9% above fair value)
  • GF Score™: 22/100 with 5 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
22GF Score

Get the complete analysis for BUE:ROSE

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS149.50
Price
ARS65.90
GF Value